Sin resumen
Murillo-Godínez G. ¿Cuánto es hipocoleste-rolemia y las patologías asociadas? Rev Med Inst Mex Seguro Soc 2009;47(1):4-6.
Pérez-Guzmán C, Vargas MH, Torres-Cruz A, Villarreal-Velarde H. Tuberculosis miliar en tuberculosis de reactivación. Informe de 36 pacientes y comparación con las formas puras. Rev Inst Nac Enf Respir 1999;12:19-28.
Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the confe-rence on low blood cholesterol: mortality asso-ciations. Circulation 1992;86:1046-1060
Mahley RW, Bersot TP. Farmacoterapia para hipercolesterolemia y dislipidemia. En: Brunton LL, Lazo JS, Parker KL, editores. Goodman and Gilman. Las bases farmacológicas de la terapéutica. México: McGraw-Hill Interame-ricana;2007. p. 945.
Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-282.
Welty FK, Lahoz C, Tucker KL, et al. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol 1998;18:1745-1751.
Appleby PN, Thorogood M, Mann JJ, Key TJ. The Oxford Vegetarian Study: an over-view. Am J Clin Nutr 1999;70(suppl): 525S-531S.
Neaton JD, Blackburn H, Jacobs D. Mul-tiple Risk Factor Intervention Trial Re-search Group. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Arch Intern Med 1992;152:1490-1500.
Grundy SM, Cleeman JI, Merz CN. Impli-cations of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-379.